Astellas fails in bid to continue US patent case against generic drug manufacturers over Myrbetriq
A US district court ruled that Astellas Pharmaceutical cann't supplement its Abbreviated New Drug Application complaint against generic drug manufacturers with traditional patent infringement claims, after generic manufacturers released their allegedly...To view the full article, register now.
Already a subscriber? Click here to view full article